Slentrol — The Dog Weight Loss Drug That Got Pulled

Slentrol (dirlotapide) was the first FDA-approved weight loss drug for dogs. Pfizer Animal Health received FDA approval in January 2007. It was a microsomal triglyceride transfer protein (MTP) inhibitor — not a GLP-1 — that worked by reducing fat absorption in the intestine. Pfizer voluntarily discontinued the product in 2013 for commercial reasons, ending the world's only veterinary weight loss drug for the next 13 years.

How Slentrol Worked

Slentrol contained dirlotapide, a selective MTP inhibitor. By blocking lipid absorption in enterocytes (intestinal cells), Slentrol caused dogs to absorb fewer calories from fat. The unabsorbed fat was excreted, similar to how orlistat works in humans. Dogs typically saw measurable weight loss within 2-3 months on the drug.

Why Pfizer Pulled It

1. Limited owner adoption. Slentrol required oral dosing 1-2 times per day for 6-12 months. Pill compliance is notoriously poor in dogs.
2. Vet hesitation on side effects. Dogs commonly experienced soft stool, diarrhea, and occasional vomiting on Slentrol — unsurprising given the mechanism.
3. Cheaper alternatives worked. Weight management food costs $50-80/month versus Slentrol's higher per-month cost, and food worked for the majority of dogs.
4. No reimbursement infrastructure. Pet insurance covered weight loss drugs inconsistently.

What Slentrol Means for Pet GLP-1 Today

Both Okava's OKV-119 and Akston's AKS-562c face the Slentrol problem. Approval gets them on the market, but commercial success requires solving for compliance, efficacy, pricing, and side effects in ways Slentrol could not.